Skip to content
NBDC Human Database

No datasets in the cart.

Go to the cart

Due to system maintenance, the application system, application review by the Data Access Committee will be unavailable during the following period.
Schedule: October 5th (Mon), 2026, 9:00 - October 7th (Wed), 2026, 15:00 (JST)
We apologize for any inconvenience this may cause and appreciate your understanding.

We are currently receiving a large number of applications for data submission, and the review process is taking longer than usual.We sincerely apologize for the delay and kindly ask for your understanding. When submitting an application, we would greatly appreciate it if you could allow sufficient time for the processing.

Following a change to our organizational structure effective April 1, 2026, this division has been renamed from the "Database Center for Life Science, Joint Support-Center for Data Science Research" to the "Database Division for Life Science (DBCLS), BioData Science Initiative (BSI), National Institute of Genetics (NIG)". Where the former name still appears in the guidelines, please read it as the new name.

Research ID

hum0384-v2Release info

Latest

Research title

Deciphering molecular mechanisms underlying hematological malignancies and development of novel therapeutic approaches

Research overview

Aims
To identify genomic/epigenomic/transcriptomic features dysregulated in hematological malignancies through genomic/epigenetic/transcriptomic analyses of hematological malignant cells. Regarding identified epigenomic abnormalities, we perform further analysis to determine whether they could be good candidates to translate into therapy development. To this end, we will modulate the activity of targets by using their activators and inhibitors in vitro and establish xenograft mouse models of hematological malignancies and manipulate their activity in vivo. Through these studies, we develop new therapeutic agents or modalities that lead to improved patients' prognoses.
Methods
A part of bone marrow aspirates (3 ml) obtained to perform a definite diagnosis will be provided for this study. Mononuclear cells are separated by gradient separation using Ficoll, then subjected to magnetic beads separation to purify CD34+ hematopoietic stem and progenitor cells (HSPCs). CD34+ HSPCs are subjected to RNA sequencing, target capture sequencing and ATAC sequencing analyses.
Participants/materials
acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) specimens were collected at Komagome Hospital and its affiliated city hospitals. Normal cells were purchased from Lonza.
URL
N/A

Datasets

CartDataset IDType of dataAnalysis methodAccess criteriaDate published
JGAD000732NGS (RNA-seq, Target Capture)
  • RNA-seq
  • Targeted DNA sequencing
Controlled-access (Type I)2024-06-20
JGAD000851NGS (RNA-seq, ATAC-seq)
  • RNA-seq
  • ATAC-seq
Controlled-access (Type I)2024-06-20

Data provider

Principal investigator
Atsushi Iwama
Affiliation
Division of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, Institute of Medical Science, University of Tokyo

Research projects

No research projects.

Grants

NameTitleProject number
KAKENHI Grant-in-Aid for Scientific Research (C)
Molecular basis of MDS pathogenesis and construction of novel MDS prognostic model
  • 21K08366
KAKENHI Grant-in-Aid for Scientific Research (C)
Elucidation of MDS molecular pathogenesis by chromatin characterization
  • 24K11554

Related publications

No related publications.

Controlled access users

No use of the controlled access data has been recorded.